<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="31530">Edaravone</z:chebi>, a novel <z:chebi fb="11" ids="22586">antioxidant</z:chebi>, acts by trapping <z:chebi fb="1" ids="29191">hydroxyl radicals</z:chebi>, quenching active oxygen and so on </plain></SENT>
<SENT sid="1" pm="."><plain>Its cardioprotective activity against experimental autoimmune <z:mp ids='MP_0001856'>myocarditis</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e>) was reported </plain></SENT>
<SENT sid="2" pm="."><plain>Nevertheless, it remains to be determined whether <z:chebi fb="0" ids="31530">edaravone</z:chebi> protects against cardiac remodelling in <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> (<z:chebi fb="20" ids="15767">DCM</z:chebi>) </plain></SENT>
<SENT sid="3" pm="."><plain>The present study was undertaken to assess whether <z:chebi fb="0" ids="31530">edaravone</z:chebi> attenuates <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo>, and examine the effect of <z:chebi fb="0" ids="31530">edaravone</z:chebi> on cardiac function in rats with <z:chebi fb="20" ids="15767">DCM</z:chebi> after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Rat model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EAM</z:e> was prepared by injection with porcine cardiac myosin 28 days after immunization, we administered <z:chebi fb="0" ids="31530">edaravone</z:chebi> intraperitoneally at 3 and 10 mg/kg/day to rats for 28 days </plain></SENT>
<SENT sid="5" pm="."><plain>The results were compared with vehicle-treated rats with <z:chebi fb="20" ids="15767">DCM</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Cardiac function, by haemodynamic and echocardiographic study and histopathology were performed </plain></SENT>
<SENT sid="7" pm="."><plain>Left ventricular (LV) expression of <z:chebi fb="1" ids="16474">NADPH</z:chebi> oxidase subunits (p47(phox) , p67(phox) , gp91(phox) and Nox4), <z:mp ids='MP_0003045'>fibrosis</z:mp> markers (TGF-β(1) and OPN), endoplasmic reticulum (ER) stress markers (GRP78 and GADD 153) and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> markers (<z:chebi fb="0" ids="4056">cytochrome</z:chebi> C and caspase-3) were measured by Western blotting </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="31530">Edaravone</z:chebi>-treated <z:chebi fb="20" ids="15767">DCM</z:chebi> rats showed better cardiac function compared with those of the vehicle-treated rats </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, LV expressions of <z:chebi fb="1" ids="16474">NADPH</z:chebi> oxidase subunits levels were significantly down-regulated in <z:chebi fb="0" ids="31530">edaravone</z:chebi>-treated rats </plain></SENT>
<SENT sid="10" pm="."><plain>Furthermore, the number of collagen-III positive cells in the myocardium of <z:chebi fb="0" ids="31530">edaravone</z:chebi>-treated rats was lower compared with those of the vehicle-treated rats </plain></SENT>
<SENT sid="11" pm="."><plain>Our results suggest that <z:chebi fb="0" ids="31530">edaravone</z:chebi> ameliorated the progression of <z:chebi fb="20" ids="15767">DCM</z:chebi> by modulating oxidative and ER stress-mediated myocardial <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and <z:mp ids='MP_0003045'>fibrosis</z:mp> </plain></SENT>
</text></document>